跳至主要内容
临床试验/NCT01703026
NCT01703026已完成不适用

Contrast Enhanced EUS Using Definity in the Evaluation of Pancreatic Cancer and Pancreatic Masses

Changi General Hospital1 个研究点 分布在 1 个国家目标入组 33 人开始时间: 2009年8月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
33
试验地点
1

研究概览

简要总结

Contrast enhanced EUS with the sonographic contrast agent DEFINITY™ has the potential to detect pancreatic cancer at an earlier stage, to improve current method of T staging and assessment of surgical resectability and also to distinguish between benign and malignant pancreatic masses. All these will translate into better clinical outcome, and also avoid unnecessary surgery in situations of unresectable cancers.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
21 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Consecutive patients over a 1-year period referred for EUS examination due to suspected pancreatic lesions will be enrolled.
  • Age 21 years and above.
  • Ability to provide informed consent

排除标准

  • Patients with clinical conditions that preclude the use of DEFINITY™ will be excluded. These conditions are:
  • Right-to-left, bi-directional, or transient right-to-left cardiac shunts;
  • Worsening or clinically unstable congestive heart failure;
  • Acute myocardial infarction or acute coronary syndromes;
  • Serious ventricular arrhythmias or high risk for arrhythmias due to prolongation of the QT interval;
  • Respiratory failure;
  • Severe emphysema, pulmonary emboli or other conditions that cause pulmonary hypertension due to compromised pulmonary arterial vasculature;
  • Hypersensitivity to DEFINITY™ or its components.

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验